These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

196 related items for PubMed ID: 25422355

  • 1. Key drivers of biomedical innovation in cancer drug discovery.
    Huber MA, Kraut N.
    EMBO Mol Med; 2015 Jan; 7(1):12-6. PubMed ID: 25422355
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Redefining cancer research.
    Alberts B.
    Science; 2009 Sep 11; 325(5946):1319. PubMed ID: 19745119
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Factors influencing development of new therapeutics for oncology.
    Winquist RJ, Boucher DM.
    Curr Opin Pharmacol; 2010 Aug 11; 10(4):353-5. PubMed ID: 20634136
    [No Abstract] [Full Text] [Related]

  • 7. Overcoming cancer resistance.
    Cook KL, Clarke R.
    Future Med Chem; 2015 Aug 11; 7(12):1471. PubMed ID: 26334204
    [No Abstract] [Full Text] [Related]

  • 8. The era of cancer discovery.
    Cantley LC, Baselga J.
    Cancer Discov; 2011 Jun 11; 1(1):1. PubMed ID: 22586302
    [No Abstract] [Full Text] [Related]

  • 9. Facilitating patient-centered cancer research and a new era of drug discovery.
    Niederhuber JE.
    Oncologist; 2009 Apr 11; 14(4):311-2. PubMed ID: 19365096
    [No Abstract] [Full Text] [Related]

  • 10. Overcoming multidrug resistance in cancer: 35 years after the discovery of ABCB1.
    Gillet JP, Gottesman MM.
    Drug Resist Updat; 2012 Apr 11; 15(1-2):2-4. PubMed ID: 22465109
    [No Abstract] [Full Text] [Related]

  • 11. Somatic alterations as the basis for resistance to targeted therapies.
    Blair BG, Bardelli A, Park BH.
    J Pathol; 2014 Jan 11; 232(2):244-54. PubMed ID: 24114654
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Genetic and epigenetic factors in anticancer drug resistance.
    Shoemaker RH.
    J Natl Cancer Inst; 2000 Jan 05; 92(1):4-5. PubMed ID: 10620620
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Targeting autophagy to overcome drug resistance in cancer therapy.
    Kumar A, Singh UK, Chaudhary A.
    Future Med Chem; 2015 Aug 05; 7(12):1535-42. PubMed ID: 26334206
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. At a crossroads in oncology.
    Kamb A.
    Curr Opin Pharmacol; 2010 Aug 05; 10(4):356-61. PubMed ID: 20542731
    [Abstract] [Full Text] [Related]

  • 18. Crossroad between linear and nonlinear transcription concepts in the discovery of next-generation sequencing systems-based anticancer therapies.
    Roukos DH.
    Drug Discov Today; 2016 Apr 05; 21(4):663-73. PubMed ID: 26912452
    [Abstract] [Full Text] [Related]

  • 19. New directions in cancer research 2003: technological advances in biology, drug resistance, and molecular pharmacology.
    Franks ME, Macpherson GR, Lepper ER, Figg WD, Sparreboom A.
    Drug Resist Updat; 2003 Dec 05; 6(6):301-12. PubMed ID: 14744494
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.